Optimización de la antibioticoterapia, una estrategia en contra de la multirresistencia microbiana

Autores/as

  • María Virginia Villegas Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM),
  • Cristhian Hernández-Gómez Grupo de Investigaciones en Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH) Universidad El Bosque,

DOI:

https://doi.org/10.18270/rsb.v7i1.2091

Palabras clave:

Multirresistencia microbiana,

Resumen

Editorial

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

María Virginia Villegas, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM),

Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia

Cristhian Hernández-Gómez, Grupo de Investigaciones en Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH) Universidad El Bosque,

Grupo de Investigaciones en Resistencia Antimicrobiana y Epidemiología
Hospitalaria (RAEH), Universidad El Bosque,
Bogotá, D.C., Colombia

Referencias bibliográficas

Macdougall C, Polk RE, Campus V. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev.2005;18:638-56.

Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014;59(Suppl.3):S97-100.

Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P, et al. Vital signs: Improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63:194-200.

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC; 2013.

U.S. Department of Health and Human Services. National action plan to prevent healthcare-associated infections: Roadmap to elimination. Fecha de consulta: 31 de octubre de 2014. Disponible en: http://1.usa.gov/17FlqsO.

Pope SD, Dellit TH, Owens RC, Hooton TM. Results of survey on implementation of Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Infect Control Hosp Epidemiol. 2009;30:97-8.

Karam GH. Understanding trends in antibiotic resistance: Focus on the hospital environment. Adv Stud Med. 2004;4:262-8.

Rosenberg DJ. Infections, bacterial resistance, and antimicrobial stewardship: The emerging role of hospitalists. J Hosp Med. 2012;7(Suppl.1): 334- 343

Fishman N. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33:322-7.

Cooke FJ, Holmes AH. The missing care bundle: Antibiotic prescribing in hospitals. Int J Antimicrob Agents. 2007;30:25-9.

Avdic E, Cushinotto LA, Hughes AH, Hansen AR, Efird LE, Bartlett JG, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54:1581-7.

Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: The evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32:367-74.

Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. J Am Med Assoc. 2003;290:2588-98.

Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gramnegative bacteria collected in the United States. Clin Ther. 2010;32:766-79.

Kuo HY, Chang KC, Kuo JW, Yueh HWA, Liou ML. Imipenem: A potent inducer of multidrug resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 2012;39:33-8.

Goldstein EJC, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into a hospital formulary: Effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:5122-6.

Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: A retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742-8.

Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4:519-27.

Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, et al. Optimal management therapy for Pseudomonas aeruginosa ventilatorassociated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888-95.

Peña C, Suárez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: A post hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57:208-16.

Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream

infections caused by carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis. 2012;55:943-50.

Descargas

Publicado

2017-10-23

Cómo citar

Villegas, M. V., & Hernández-Gómez, C. (2017). Optimización de la antibioticoterapia, una estrategia en contra de la multirresistencia microbiana. Revista Salud Bosque, 7(1), 5–9. https://doi.org/10.18270/rsb.v7i1.2091

Número

Sección

Editorial